Nectar Lifesciences Limited Q2 Loss Widens to ₹22.09 Crore

Nectar Lifesciences Limited reported a ₹22.09 crore net loss for the quarter ended September 30, 2026, compared with a ₹13.46 crore loss in the preceding quarter. Total comprehensive loss widened to ₹292.81 crore from ₹13.14 crore, according to the outcome of its board meeting held on November 14, 2026.

Why did Nectar Lifesciences report a wider September-quarter loss?

Nectar Lifesciences reported a wider net loss in its unaudited financial results for the September 2026 quarter, although the supplied disclosure does not provide a detailed explanation for the movement. The board approved standalone and consolidated results for the quarter and half year ended September 30, 2026.

The reported net loss was ₹22.09 crore, against a prior-quarter loss of ₹13.46 crore. Total comprehensive loss, which includes profit or loss and other comprehensive income, was ₹292.81 crore against ₹13.14 crore in the preceding quarter. The company has not provided a breakup in the supplied information to reconcile the difference between net loss and total comprehensive loss.

The September quarter is generally referred to as Q2 of FY27, covering July 1, 2026 to September 30, 2026. The results were considered at a board meeting scheduled for November 14, which was also the outer disclosure deadline for the quarter under the stated 45-day listing requirement.

What did the Nectar Lifesciences board approve on November 14?

The Nectar Lifesciences board approved unaudited standalone and consolidated financial results for the September 2026 quarter and the first half of FY27. The company had earlier informed BSE and NSE that the board would consider these results along with other business matters.

Ahead of the results, the company closed its trading window for designated persons and their immediate relatives from October 1, 2026 until 48 hours after the results declaration. This was stated to be in line with its code of conduct and applicable SEBI regulations.

Nectar Lifesciences also submitted a compliance certificate for the September quarter under Regulation 74(5) of the SEBI Depositories and Participants Regulations, 2018. The certificate was received from Kfin Technologies Limited, the company’s registrar and share transfer agent.

How does the result compare with Nectar Lifesciences' recent financial history?

The September-quarter loss follows a financially disruptive FY26 for Nectar Lifesciences. The company reported a net loss of ₹2,928.85 crore for FY26 after exiting its Active Pharmaceutical Ingredients and formulation businesses through a slump sale to Ceph Lifesciences Private Limited.

The sale of the pharma business generated an exceptional gain of ₹1,633.73 crore under discontinued operations. However, the supplied information says this was outweighed by a pre-tax loss of ₹5,376.55 crore from discontinued operations and a pre-tax loss of ₹878.70 crore from continuing operations.

Revenue from operations was nil in FY26 following the business disposal. Earlier reported figures cited in the source showed revenue of ₹0 crore in Q1 FY27, compared with ₹5 crore in Q1 FY26, while the Q2 FY26 comparison base showed revenue of ₹1 crore and a loss of ₹176 crore. These figures indicate that comparisons with prior periods are affected by the exit from the operating pharma business.

What does the September result mean for investors and operations?

The September-quarter result keeps investor attention on Nectar Lifesciences' post-pharma transition and on the components behind its comprehensive loss. A ₹292.81 crore total comprehensive loss is materially larger than the reported ₹22.09 crore net loss, but the supplied board-meeting outcome does not explain the underlying items.

The company had stated that it became debt-free and held ₹1,081.30 crore in cash after the pharma-business transaction. It has also entered the real estate sector through Avensis Exports Private Limited. The September results are therefore being assessed against a business structure that differs significantly from its earlier pharmaceutical operations.

For shareholders, the results provide a timely regulatory update but do not, based on the supplied information, establish a revenue trend for the new structure. The company remains listed on BSE and NSE and has stated that it follows SEBI listing and corporate-governance disclosure requirements.

Conclusion

Nectar Lifesciences' September 2026 quarter showed a net loss of ₹22.09 crore, wider than the preceding quarter's ₹13.46 crore loss, alongside a ₹292.81 crore total comprehensive loss. The figures come after FY26, when the company disposed of its core pharma businesses and recorded substantial losses despite an exceptional gain from the transaction.

Investors will watch for detailed financial statements and notes that explain the comprehensive-loss movement, the performance of continuing operations and any revenue contribution from the company's real estate entry. Further disclosures on the post-slump-sale business structure will be important for assessing comparability with earlier periods.